NasdaqGM:CGEN

Stock Analysis Report

Executive Summary

Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe.

Risk Analysis

Earnings are forecast to decline by an average of -0.4% per year for the next 3 years

Makes less than USD$1m in revenue ($0)

Currently unprofitable and not forecast to become profitable over the next 3 years

Highly volatile share price over past 3 months

+ 1 more risk


Snowflake Analysis

Flawless balance sheet with weak fundamentals.


Similar Companies

Share Price & News

How has Compugen's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: CGEN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-1.1%

CGEN

1.6%

US Life Sciences

1.7%

US Market


1 Year Return

91.8%

CGEN

28.5%

US Life Sciences

23.2%

US Market

Return vs Industry: CGEN exceeded the US Life Sciences industry which returned 29.7% over the past year.

Return vs Market: CGEN exceeded the US Market which returned 24.7% over the past year.


Shareholder returns

CGENIndustryMarket
7 Day-1.1%1.6%1.7%
30 Day2.9%5.2%4.2%
90 Day55.9%17.5%11.9%
1 Year91.8%91.8%28.8%28.5%25.8%23.2%
3 Year32.2%32.2%110.7%109.0%52.8%42.9%
5 Year-25.4%-25.4%140.4%137.1%75.2%55.8%

Price Volatility Vs. Market

How volatile is Compugen's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Compugen undervalued compared to its fair value and its price relative to the market?

9.5x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate CGEN's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate CGEN's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: CGEN is unprofitable, so we can't compare its PE Ratio to the Life Sciences industry average.

PE vs Market: CGEN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate CGEN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: CGEN is overvalued based on its PB Ratio (9.1x) compared to the US Life Sciences industry average (5.3x).


Next Steps

Future Growth

How is Compugen forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

-0.4%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: CGEN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: CGEN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: CGEN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: CGEN is forecast to have no revenue next year.

High Growth Revenue: CGEN is forecast to have no revenue next year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if CGEN's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Compugen performed over the past 5 years?

-12.6%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: CGEN is currently unprofitable.

Growing Profit Margin: CGEN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: CGEN is unprofitable, and losses have increased over the past 5 years at a rate of -12.6% per year.

Accelerating Growth: Unable to compare CGEN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: CGEN is unprofitable, making it difficult to compare its past year earnings growth to the Life Sciences industry (34.6%).


Return on Equity

High ROE: CGEN has a negative Return on Equity (-72.32%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Next Steps

Financial Health

How is Compugen's financial position?


Financial Position Analysis

Short Term Liabilities: CGEN's short term assets ($48.4M) exceed its short term liabilities ($6.7M).

Long Term Liabilities: CGEN's short term assets ($48.4M) exceed its long term liabilities ($8.7M).


Debt to Equity History and Analysis

Debt Level: CGEN is debt free.

Reducing Debt: CGEN has not had any debt for past 5 years.


Balance Sheet

Inventory Level: CGEN has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if CGEN's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: CGEN has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: CGEN has sufficient cash runway for 2.2 years if free cash flow continues to grow at historical rates of 13.9% each year.


Next Steps

Dividend

What is Compugen's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%1.4%markettop25%3.6%industryaverage0.3%forecastin3Yearsn/a

Current dividend yield vs market & industry

Notable Dividend: Unable to evaluate CGEN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate CGEN's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if CGEN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if CGEN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of CGEN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

What is the CEO of Compugen's salary, the management and board of directors tenure and is there insider trading?

3.1yrs

Average management tenure


CEO

Anat Cohen-Dayag (52yo)

9.8yrs

Tenure

US$854,003

Compensation

Dr. Anat Cohen-Dayag, Ph.D., has been the Chief Executive Officer at Compugen Ltd. since March 2010 and serves as its President since June 2009. Dr. Cohen-Dayag served as Vice President of Research & Devel ...


CEO Compensation Analysis

Compensation vs Market: Anat's total compensation ($USD854.00K) is below average for companies of similar size in the US market ($USD1.70M).

Compensation vs Earnings: Anat's compensation has increased whilst the company is unprofitable.


Management Age and Tenure

3.1yrs

Average Tenure

51.5yo

Average Age

Experienced Management: CGEN's management team is considered experienced (3.1 years average tenure).


Board Age and Tenure

6.4yrs

Average Tenure

62yo

Average Age

Experienced Board: CGEN's board of directors are considered experienced (6.4 years average tenure).


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 15.8%.


Management Team

  • Martin Gerstel (78yo)

    Senior Advisor

    • Tenure: 1.9yrs
  • Elana Holzman

    Director of Investor Relations & Corporate Communications

    • Kirk Christoffersen (50yo)

      Senior Vice President of Corporate & Business Development

      • Tenure: 3.1yrs
      • Compensation: US$639.39k
    • Anat Cohen-Dayag (52yo)

      CEO, President & Director

      • Tenure: 9.8yrs
      • Compensation: US$854.00k
    • Dorit Amitay (51yo)

      Vice President of Human Resources

      • Tenure: 13yrs
    • Donna Gershowitz (55yo)

      General Counsel

      • Ari Krashin (46yo)

        Chief Financial & Operating Officer

        • Tenure: 5.3yrs
        • Compensation: US$575.74k
      • Zurit Levine (51yo)

        Senior Vice President of Technology Innovation

        • Compensation: US$356.02k
      • John Hunter (56yo)

        Chief Scientific Officer

        • Tenure: 1.3yrs
        • Compensation: US$602.79k
      • Henry Adewoye

        Chief Medical Officer

        • Tenure: 1.8yrs
        • Compensation: US$612.73k

      Board Members

      • Sandy Zweifach (63yo)

        Director

        • Tenure: 1.6yrs
      • Arie Ovadia (71yo)

        External Director

        • Tenure: 12.5yrs
      • Paul Sekhri (61yo)

        Chairman

        • Tenure: 2.3yrs
      • Kinneret Livnat-Savitzky (52yo)

        Director

        • Tenure: 1.6yrs
      • Drew Pardoll

        Chairman of Scientific Advisory Board

        • Anat Cohen-Dayag (52yo)

          CEO, President & Director

          • Tenure: 9.8yrs
          • Compensation: US$854.00k
        • Yair Aharonowitz (78yo)

          External Director

          • Tenure: 12.5yrs
        • Toni Ribas

          Member of Scientific Advisory Board

          • Tenure: 6.4yrs
        • Iain McInnes

          Member of Scientific Advisory Board

          • Tenure: 6.4yrs
        • Charles Drake

          Member of Scientific Advisory Board

          • Tenure: 6.4yrs

        Company Information

        Compugen Ltd.'s company bio, employee growth, exchange listings and data sources


        Key Information

        • Name: Compugen Ltd.
        • Ticker: CGEN
        • Exchange: NasdaqGM
        • Founded: 1993
        • Industry: Life Sciences Tools and Services
        • Sector: Pharmaceuticals & Biotech
        • Market Cap: US$376.692m
        • Shares outstanding: 61.96m
        • Website: https://www.cgen.com

        Number of Employees


        Location

        • Compugen Ltd.
        • Building D
        • 26 Harokmim Street
        • Holon
        • 5885849
        • Israel

        Listings

        TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
        CGENNasdaqGM (Nasdaq Global Market)YesOrdinary SharesUSUSDAug 2000
        CGENTASE (The Tel-Aviv Stock Exchange)YesOrdinary SharesILILSAug 2000
        CW9DB (Deutsche Boerse AG)YesOrdinary SharesDEEURAug 2000

        Biography

        Compugen Ltd., a therapeutic discovery company, engages in the research, development, and commercialization of therapeutic and product candidates in Israel, the United States, and Europe. The company’s therapeutic pipeline consists of immuno-oncology programs against novel drug targets, including T cell immune checkpoints and other early-stage immuno-oncology programs focusing on myeloid target. Its product pipeline consists of COM701, a therapeutic antibody that is in phase I clinical trials for PVRIG; BAY 1905254, a therapeutic antibody that is in phase I clinical trials for ILDR2; and COM902, a therapeutic immuno-oncology antibody for TIGIT program. Compugen Ltd. has a collaboration agreement with Bristol-Myers Squibb Company to evaluate the safety of COM701 in combination with Bristol-Myers Squibb’s programmed death-1 immune checkpoint inhibitor Opdivo in patients with advanced solid tumors; and license agreement with MedImmune Limited for the development of bi-specific and multi-specific immuno-oncology antibody products. The company was incorporated in 1993 and is headquartered in Holon, Israel. 


        Company Analysis and Financial Data Status

        All financial data provided by Standard & Poor's Capital IQ.
        DataLast Updated (UTC time)
        Company Analysis2020/01/17 01:40
        End of Day Share Price2020/01/16 00:00
        Earnings2019/09/30
        Annual Earnings2018/12/31


        Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.